Clinical Trial Update: Lurtotecan Liposome in Treating Patients With Advanced or Recurrent Ovarian Epithelial Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating lurtotecan liposome in advanced or recurrent ovarian epithelial cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cavity Cancer

Drugs mentioned

• Lurtotecan Liposome (lurtotecan liposome)

Snippet

Sponsor: NCIC Clinical Trials Group | Conditions: Fallopian Tube Cancer, Ovarian Cancer | Phase 2 | Status: COMPLETED